Integration of ceritinib and bevacizumab as a promising treatment
strategy for brain metastases from ALK mutation-position non-small cell
lung cancer: a case report
Ceritinib shows efficacy in ALK+ NSCLC patients with BM. However, the
disease will inevitably progress over time due to acquired resistance.
We now report a case with BM from advanced lung adenocarcinoma with ALK
mutations who exhibited a surprising and long-term response to treatment
of ceritinib combined with bevacizumab.